Side-by-side · Research reference

SemaxvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft12/39 cited

BPhase 2Reviewed8/46 cited

Semax

Cognitive enhancer · Russian Pharma

200–600 mcg/doseIntranasalKaplan 2017

HumanMechanisticKaplan 2017

~30 minOnset

Intranasal · 2–3×/day during cognitive demand

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Semax

TB-500

Primary target

BDNF / NGF expression + monoamine modulationKaplan 2017

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

↑ BDNF + NGF synthesis + 5-HT modulation → neuroplasticity + anxiolysis + cognitive enhancementKaplan 2017

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Improved memory + attention; reduced anxiety; neuroprotection in ischemiaKaplan 2017

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Synthetic 7-AA peptide derived from ACTH(4-7) with C-terminal Pro-Gly-Pro stabilising tailKaplan 2017

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Semax

TB-500

Standard dose

200–600 mcg / dose intranasalKaplan 2017

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

2–3× per day during cognitive demand

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

100 mcg / dose

1 mg per injection

Evidence basis

Human-mechanistic + Russian clinicalKaplan 2017

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration

10–14 day cycles, repeated PRN

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

Morning + early afternoon

Evening or pre-rest preferred (anecdotal)

Half-life

Short plasma; CNS effect lasts ~3–6 hr

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

Semax

TB-500

Nasal irritation

Mild burning or congestion (transient)

—

Sleep disruption

Late-day dosing may interfere with sleep

—

Headache

Uncommon, transient

—

Long-term safety

Limited Western RCT data

Unknown beyond Phase 2

Pregnancy / OB

Avoid

Injection site reaction

—

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Absolute Contraindications

Semax

·Pregnancy / breastfeeding

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Semax

·Active psychiatric instability
·Concurrent strong stimulants

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Semax

TB-500

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Administration

Intranasal — 2–3 sprays per nostril per dose. Tilt head slightly back.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Timing

Morning + early afternoon. Avoid evening (sleep disruption).

Evening or pre-sleep is most common anecdotal timing.

4. Storage

Refrigerate after reconstitution; light-protected.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Caveat

Cycle on/off to avoid neurochemical adaptation.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Semax

+ Selank

Moderate

View Selank →

Semax (cognitive enhancer, BDNF/NGF) and Selank (anxiolytic + immune) form the canonical Russian "neuro stack" — both intranasal peptide bioregulators with complementary axes. Semax for cognitive demand; Selank for stress mitigation.

Semax: 200–600 mcg intranasal · morning + afternoon
Selank: 150–300 mcg intranasal · midday + early evening
Primary benefit: Cognitive enhancement + stress mitigation

Kaplan 2017 Zaderej 2014

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair